Journal profile · Neurosciences
CNS & Neurological Disorders-Drug Targets
ISSN 1871-5273 · eISSN 1996-3181 · Bentham Science Publishers B.V. · U ARAB EMIRATES · Bimonthly · Founded 2006
CNS & Neurological Disorders-Drug Targets: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.32; subscription journal; median 93 days to acceptance (72 articles, last 24 months); community-reported acceptance: fairly hard; 78 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
CNS & Neurological Disorders-Drug Targets is published by Bentham Science Publishers B.V. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Alzheimer's disease research and treatments, Tryptophan and brain disorders and Cholinesterase and Neurodegenerative Diseases, together about 23.8% of its articles. Its main subfields are Neurology. (generated from OpenAlex topic counts and CAS ranking data)
Aims & Scope CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
Source: LetPub
Research area (LetPub): Neurosciences
Main research topics OpenAlex counts of recent articles; shares are approximate
- Alzheimer's disease research and treatmentsMedicine9.5%
- Tryptophan and brain disordersNeuroscience7.6%
- Cholinesterase and Neurodegenerative DiseasesMedicine6.7%
- Neuroscience and Neuropharmacology ResearchNeuroscience6.6%
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience6%
- Parkinson's Disease Mechanisms and TreatmentsMedicine5.6%
- Neurological Disorders and TreatmentsNeuroscience4.2%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Neurosciences | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Neurosciences | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Neurosciences | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.32LetPub ·
- CiteScore 2026-06
- 7.3LetPub ·
- SJR 2026-06
- 0.79LetPub ·
- SNIP 2026-06
- 0.8LetPub ·
- h-index
- 78LetPub ·
- h-index
- 115OpenAlex ·
- i10-index
- 1,411OpenAlex ·
- 2-year mean citedness
- 2.22OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 1.48%LetPub ·
Volume
- Articles per year
- 77LetPub ·
Articles by year OpenAlex count · 2,486 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 131 | 3 | 31 |
| 2025 | 78 | 3 | 181 |
| 2024 | 60 | 1 | 386 |
| 2023 | 99 | 6 | 812 |
| 2022 | 146 | 5 | 1,348 |
| 2021 | 151 | 10 | 2,202 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
93 daysMedian, submission to acceptance · P25–P75 74 days – 110 days
- Acceptance to online
- median 175 days (72 articles)
- Submission to online
- median 259 days
- Sample
- 72 articles with submission and acceptance dates (271 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- U ARAB EMIRATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2006
- ISSN
- 1871-5273
- Electronic ISSN
- 1996-3181
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about CNS & Neurological Disorders-Drug Targets
What CAS zone is CNS & Neurological Disorders-Drug Targets in?
In the 2025 upgraded edition of the CAS Journal Ranking, CNS & Neurological Disorders-Drug Targets is in Zone 4 of Medicine, and in Zone 4 of the minor category Neurosciences / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of CNS & Neurological Disorders-Drug Targets?
The latest impact factor listed by LetPub is 3.32; CiteScore 7.3, h-index 115.
How long does peer review take at CNS & Neurological Disorders-Drug Targets?
Based on the dates recorded on 72 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 93 days (interquartile range 74–110 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index CNS & Neurological Disorders-Drug Targets?
According to LetPub and DOAJ records, CNS & Neurological Disorders-Drug Targets is indexed in SCIE and Scopus.
Is CNS & Neurological Disorders-Drug Targets open access, and what is the APC?
CNS & Neurological Disorders-Drug Targets is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .